Evidence map›Paper›PMID 33859475›Full record

ArticleInternational journal of nanomedicine2021

Anti-Cancer Activity Based on the High Docetaxel Loaded Poly(2-Oxazoline)s Micelles.

Min Xu, Chong Yao, Wei Zhang, Shen Gao, Hao Zou, Jing Gao

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Min Xu *School of Pharmacy, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Chong Yao *Clinical Pharmacy Center, Department of Pharmacy, Chinese PLA General Hospital, Beijing, 100850, People's Republic of China.
Wei ZhangSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Shen GaoSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, People's Republic of China.ORCID 0000-0002-5125-1606
Hao ZouSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Jing GaoSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Second Military Medical University · CNChinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNanocarriers, with a high drug loading content and good safety, to achieve desirable therapeutic effect are always the goals for industry and research. METHODS AND

resultsIn the present study, we developed a docetaxel loaded poly-2-oxazoline polymer micellar system which employed poly-2-butyl-2 oxazoline and poly-2-methyl-2 oxazoline as the hydrophobic chain and hydrophilic chain, respectively. This micellar system achieves a high load up to 25% against the docetaxel, and further demonstrates an IC50 as low as 40% of the commercialized docetaxel injection in vitro and a double maximum tolerated dose in MCF-7 cells in vivo.

conclusionThe high drug loading content, superior safety, and considerable anti-cancer activity make this newly developed docetaxel loaded poly(2-oxazoline) micelle go further in future clinical research.

Indexed as

MicellesA549 CellsAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell SurvivalDocetaxelDrug CarriersDrug LiberationEndocytosisHumansHydrophobic and Hydrophilic InteractionsMaleMaximum Tolerated DoseMCF-7 CellsAntineoplastic AgentsDocetaxelDrug CarriersMicellesOxazolespoly(2-oxazoline)Surface-Active Agentsanti-cancer activitydocetaxelhigh loadingmicellepoly(2-oxazoline)s

Identifiers

PMID33859475
PMCPMC8043799
OpenAlexW3154845825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.